(5Z,7E)-(1S,3R,20S)-1,3-bis<(tert-butyldimethylsilyl)oxy>-9,10-seco-22,23-dinor-5,7,10(19)-cholatrien-24-ol | 114694-12-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (5Z,7E)-(1S,3R,20S)-1,3-bis<(tert-butyldimethylsilyl)oxy>-9,10-seco-22,23-dinor-5,7,10(19)-cholatrien-24-ol
• 英文别名: (5Z,7E)-(1S,3R,20S)-1,3-bis[(t-butyldimethyl-silyl)oxy]-22,23-dinor-9,10-secochola-5,7,10(19)-triene-24-ol；(5Z,7E)-(1S,3R,20S)-1,3-bis[(tert-butyldimethylsilyl)oxy]-9,10-seco-22,23-dinor-5,7,10(19)-cholatrien-24-ol；(5Z,7E)-(1S,3R)-1,3-Bis[tert-butyl(dimethylsilyl)oxy]-22-hydroxy-23,24-dinor-9,10-secochola-5,7,10(19)-triene；(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(3S,5R)-3,5-bis[[tert-butyl(dimethyl)silyl]oxy]-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]propan-1-ol
• CAS: 114694-12-1
• 化学式: C₃₄H₆₂O₃Si₂
• 分子量: 575.035
• InChiKey: WBUHPAHBCMHESO-FLJNKPCASA-N

物化性质

• 沸点：
  572.7±50.0 °C(Predicted)
• 密度：
  0.96±0.1 g/cm3(Predicted)
• 溶解度：
  二氯甲烷；

计算性质

• 辛醇/水分配系数(LogP)：
  9.81
• 重原子数：
  39
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (5Z,7E)-(1S,3R,20S)-1,3-bis<(tert-butyldimethylsilyl)oxy>-9,10-seco-22,23-dinor-5,7,10(19)-cholatrien-24-ol 在 4-二甲氨基吡啶 、 lithium carbonate 、 三乙胺 、 lithium bromide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 30.83h， 生成 (5Z,7E)-(1S,3R)-1,3-bis[(t-butyldimethyl-silyl)oxy]-24-phenylsulfonyl-22,23-dinor-9,10-secochola-5,7,10(19)-triene
  参考文献：
  名称：

  Synthesis and antiproliferative activity of side-chain unsaturated and homologated analogs of 1,25-dihydroxyvitamin D2

  摘要：

  A series of analogs of 1,25-dihydroxyergocalciferol (1-4) was synthesized and screened for their antiproliferative activity in vitro. The structure of new analogs was designed based on biological activity of the previously obtained side-chain modified analogs of vitamin D-2 and D-3. The analogs were obtained by the Julia olefination of C-22-vitamin D sulfone 11 with side-chain aldehyde 15. The analogs were tested for their antiproliferative activity against the cells of human breast cancer lines T47D and MCF7 as well as human and mouse leukemia lines, HL-60 and WEHI-3, respectively. Analog 2 (PRI-1907) showed the strongest antiproliferative activity out of the present series of analogs of 1,25-dihydroxyvitamin D-2 with the mono homologated and double unsaturated side chain. The activity of 2 was 3-150 times stronger, depending on the cell line, than that of 1,25-dihydroxycholecalciferol (calcitriol), used as standard. (C) 2002 Elsevier Science Inc. All rights reserved.

  DOI：

  10.1016/s0039-128x(02)00038-7
• 作为产物：
  描述：

  hydroxybisnorcholenic acid 在 吡啶 、 咪唑 、 叔丁基过氧化氢 、 氢氧化钾 、 lithium aluminium tetrahydride 、 selenium(IV) oxide 、 硫酸 、 potassium hydrogencarbonate 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 50.42h， 生成 (5Z,7E)-(1S,3R,20S)-1,3-bis<(tert-butyldimethylsilyl)oxy>-9,10-seco-22,23-dinor-5,7,10(19)-cholatrien-24-ol
  参考文献：
  名称：

  Novel convergent synthesis of side-chain-modified analogs of 1.alpha.,25-dihydroxycholecalciferol and 1.alpha.,25-dihydroxyergocalciferol

  摘要：

  DOI：

  10.1021/jo00250a009

文献信息

• Vitamin D C-22 aldehydes. New key intermediates for the synthesis of side chain modified vitamin D analogues
  作者：Andrzej Kutner、Kato L. Perlman、Rafal R. Sicinski、Mary E. Phelps、Heinrich K. Schnoes、Hector F. DeLuca

  DOI：10.1016/s0040-4039(00)61826-9

  日期：1987.1

  Vitamin D C-22 aldehyde and 1α-hydroxyvitamin D C-22 aldehyde were efficiently synthesized starting from the readily available 22,23-bisnorcholenic acid. The usefulness of the compounds as common intermediates for the synthesis of side chain modified analogues of vitamins D2 and D3 has been demonstrated.

  维生素D C-22醛和1α-羟基维生素D C-22醛是从容易获得的22,23-双降胆固醇酸开始有效合成的。已经证明了该化合物作为合成维生素D 2和D 3的侧链修饰的类似物的通用中间体的有用性。
• VITAMIN D3 LACTONE DERIVATIVE
  申请人：Teijin Pharma Limited

  公开号：EP1589009B1

  公开（公告）日：2014-10-08
• EP1477483
  申请人：——

  公开号：——

  公开（公告）日：——
• Practical Synthesis and Evaluation of the Biological Activities of 1α,25-dihydroxyvitamin D₃ Antagonists, 1α,25-dihydroxyvitamin D₃-26,23-lactams. Designed on the Basis of the Helix 12-Folding Inhibition Hypothesis
  作者：Yusuke Nakano、Yuko Kato、Keisuke Imai、Eiji Ochiai、Jun-ichi Namekawa、Seiichi Ishizuka、Kazuya Takenouchi、Aya Tanatani、Yuichi Hashimoto、Kazuo Nagasawa

  DOI：10.1021/jm050738x

  日期：2006.4.1

  A practical synthetic route to novel vitamin D antagonists of DLAM (1 alpha.,25-dihydroxyvitamin D-3-26,23lactam) was developed from vitamin D-2 via the 1,3-dipolar cycloaddition reaction as a key step. Six DLAM derivatives (24 compounds) with a variety of nitrogen substituents and stereochemistries at C23 and C25 were synthesized. Among these new derivatives, (23S,25S)-DLAM isomers bound effectively to VDRs and showed antagonistic activity in the HL-60 cell differentiation inhibition assay. The importance of the substituent on the nitrogen of DLAMs for antagonistic activity was also suggested by computational docking studies.